AC
BHVN icon

Armistice Capital’s Biohaven BHVN Stock Holding History

Armistice Capital’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,136,000
Closed -$31.1M – 341
2025
Q2 		$30.1M Buy
2,136,000
+462,578
+28% +$8.24M 0.52% 30
2025
Q1 		$40.2M Buy
1,673,422
+1,124
+0.1% +$39.6K 0.6% 37
2024
Q4 		$62.5M Buy
1,672,298
+472,803
+39% +$22.1M 0.85% 22
2024
Q3 		$59.9M Sell
1,199,495
-197,473
-14% -$7.68M 0.96% 18
2024
Q2 		$48.5M Buy
1,396,968
+597,705
+75% +$23.6M 0.61% 29
2024
Q1 		$43.7M Sell
799,263
-700,737
-47% -$34.7M 0.58% 27
2023
Q4 		$64.2M Sell
1,500,000
-536,000
-26% -$16.7M 0.88% 21
2023
Q3 		$53M Buy
2,036,000
+236,000
+13% +$4.91M 0.81% 23
2023
Q2 		$43.1M Sell
1,800,000
-1,324,000
-42% -$22.8M 0.62% 36
2023
Q1 		$42.7M Buy
3,124,000
+400,000
+15% +$6.37M 0.61% 40
2022
Q4 		$37.8M Buy
2,724,000
+1,259,064
+86% +$17.8M 0.66% 36
2022
Q3 		$9.02M Buy
+1,464,936
New +$10.6M 0.16% 76

Other funds holding BHVN

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $173M AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Armistice Capital's BHVN Position: Q3 2025 in Review

Armistice Capital sold out of Biohaven (BHVN) in Q3 2025, closing a stake of 2,136,000 shares — an estimated $31.1M sold.

Armistice Capital first reported a position in BHVN in Q3 2022 and held it in 12 quarters. The position peaked at $64.2M in Q4 2023. 264 funds tracked by Wall St. Rank hold BHVN as of Q3 2025.

  • Armistice Capital reported no remaining Biohaven position as of Q3 2025 after selling out during the quarter.
  • Armistice Capital sold 2,136,000 Biohaven shares in Q3 2025, an estimated $31.1M.
  • Armistice Capital first reported a position in Biohaven in Q3 2022 and held it in 12 quarters.
  • Armistice Capital's Biohaven position peaked at $64.2M in Q4 2023.
  • 264 funds tracked by Wall St. Rank held Biohaven as of Q3 2025.

Based on Armistice Capital's 13F filing for Q3 2025, filed 17 Nov 2025.